Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
Conditions: Parenteral Nutrition Associated Liver Disease (PNALD); Essential Fatty Acid Deficiency; Malnutrition; Pediatric ALL Interventions: Drug: Omegaven ® (fish oil triglycerides) Injectable Emulsion Sponsors: Fresenius Kabi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Fish | Fish Oil | Liver | Liver Disease | Nutrition | Parenteral Nutrition | Pediatrics | Research | Study | Urology & Nephrology